




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : <b>C07D 487/04, A61K 31/505, A61P 15/00</b> // (C07D 487/04, 209:00, 239:00) (C07D 487/04, 235:00, 239:00)</p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 00/69859</b></p> <p>(43) International Publication Date: 23 November 2000 (23.11.00)</p>									
<p>(21) International Application Number: <b>PCT/US00/13108</b></p> <p>(22) International Filing Date: <b>12 May 2000 (12.05.00)</b></p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>09/310,878</td> <td>14 May 1999 (14.05.99)</td> <td>US</td> </tr> <tr> <td>09/363,254</td> <td>28 July 1999 (28.07.99)</td> <td>US</td> </tr> <tr> <td>09/405,286</td> <td>23 September 1999 (23.09.99)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): <b>NEUROCRINE BIOSCIENCES, INC.</b> [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <b>ZHU, Yun-Fei</b> [CN/US]; 7758 Prairie Shadow, San Diego, CA 92126 (US). <b>WILCOXEN, Keith, M.</b> [US/US]; 2015 - 31st Street, San Diego, CA 92104 (US). <b>STRUTHERS, R., Scott</b> [US/US]; 1161 Avenida Esteban, Encinitas, CA 92024 (US). <b>CHEN, Chen</b> [CN/US]; 13922 Sparren Avenue, San Diego, CA 92129 (US). <b>CONNORS, Patrick, Jr.</b> [US/US]; 4201 Illinois Street, San Diego, CA 92014 (US). <b>GAO, Yinghong</b> [CN/US]; 7856 Camino Tranquilo, San Diego, CA 92122 (US). <b>TUCCI, Fabio, C.</b> [BR/US]; 105550 Science Center Drive, San Diego, CA 92121 (US).</p>		09/310,878	14 May 1999 (14.05.99)	US	09/363,254	28 July 1999 (28.07.99)	US	09/405,286	23 September 1999 (23.09.99)	US	<p>(74) Agents: <b>HERMANN, Karl, R. et al.</b>; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).</p> <p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
09/310,878	14 May 1999 (14.05.99)	US									
09/363,254	28 July 1999 (28.07.99)	US									
09/405,286	23 September 1999 (23.09.99)	US									
<p>(54) Title: <b>IMIDAZO- AND PYRROLO[1,2-A]PYRIMID-4-ONES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS</b></p> <div style="text-align: center;">  <p>(I)</p> </div> <p>(57) Abstract</p> <p>GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have structure (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Ar, B, R<sub>1</sub>, R<sub>2</sub>, R<sub>3a</sub>, R<sub>3b</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and <i>m</i> are as defined herein.</p>											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## IMIDAZO- AND PYRROLO[1,2-A]PYRIMID-4-ONES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS

## TECHNICAL FIELD

This invention relates generally to gonadotropin-releasing hormone  
5 (GnRH) receptor antagonists, and to methods of treating disorders by administration of such antagonists to a warm-blooded animal in need thereof.

## BACKGROUND OF THE INVENTION

Gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH), is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-  
10 Arg-Pro-Gly-NH<sub>2</sub>) that plays an important role in human reproduction. GnRH is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH released from the pituitary gland is responsible for the regulation of gonadal steroid production in both males and females, while FSH regulates spermatogenesis in  
15 males and follicular development in females.

Due to its biological importance, synthetic antagonists and agonists to GnRH have been the focus of considerable attention, particularly in the context of prostate cancer, breast cancer, endometriosis, uterine leiomyoma, and precocious puberty. For example, peptidic GnRH agonists, such as leuprorelin (pGlu-His-Trp-Ser-  
20 Tyr-D-Leu-Leu-Arg-Pro-NHEt), have been used to treat such conditions. Such agonists appear to function by binding to the GnRH receptor in the pituitary gonadotropins, thereby inducing the synthesis and release of gonadotropins. Chronic administration of GnRH agonists depletes gonadotropins and subsequently down-regulates the receptor, resulting in suppression of steroidal hormones after some period of time (*e.g.*, on the  
25 order of 2-3 weeks following initiation of chronic administration).

In contrast, GnRH antagonists are believed to suppress gonadotropins from the onset, and thus have received the most attention over the past two decades. To date, some of the primary obstacles to the clinical use of such antagonists have been their relatively low bioavailability and adverse side effects caused by histamine release.

However, several peptidic antagonists with low histamine release properties have been reported, although they still must be delivered via sustained delivery routes (such as subcutaneous injection or intranasal spray) due to limited bioavailability.


In view of the limitations associated with peptidic GnRH antagonists, a number of nonpeptidic compounds have been proposed. For example, Cho et al. (*J. Med. Chem.* 41:4190-4195, 1998) discloses thieno[2,3-*b*]pyridin-4-ones for use as GnRH receptor antagonists; U.S. Patent Nos. 5,780,437 and 5,849,764 teach substituted indoles as GnRH receptor antagonists (as do published PCTs WO 97/21704, 98/55479, 98/55470, 98/55116, 98/55119, 97/21707, 97/21703 and 97/21435); published PCT WO 96/38438 discloses tricyclic diazepines as GnRH receptor antagonists; published PCTs WO97/14682, 97/14697 and 99/09033 disclose quinoline and thienopyridine derivatives as GnRH antagonists; published PCTs WO 97/44037, 97/44041, 97/44321 and 97/44339 teach substituted quinolin-2-ones as GnRH receptor antagonists; and published PCT WO 99/33831 discloses certain phenyl-substituted fused nitrogen-containing bicyclic compounds as GnRH receptor antagonists.

While significant strides have been made in this field, there remains a need in the art for effective small molecule GnRH receptor antagonists. There is also a need for pharmaceutical compositions containing such GnRH receptor antagonists, as well as methods relating to the use thereof to treat, for example, sex-hormone related conditions. The present invention fulfills these needs, and provides other related advantages.

#### SUMMARY OF THE INVENTION

In brief, this invention is generally directed to gonadotropin-releasing hormone (GnRH) receptor antagonists, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.

More specifically, the GnRH receptor antagonists of this invention are compounds having the following general structure (I):



(I)

including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof,  
 5 wherein Ar, B, R<sub>1</sub>, R<sub>2</sub>, R<sub>3a</sub>, R<sub>3b</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and *m* are as defined below.


The GnRH receptor antagonists of this invention have utility over a wide range of therapeutic applications, and may be used to treat a variety of sex-hormone-related conditions in both men and women, as well as a mammal in general (also referred to herein as a "subject"). For example, such conditions include endometriosis,  
 10 uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (*e.g.*, assisted reproductive therapy such as *in vitro* fertilization). The compounds of this invention are  
 15 also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosus. The compounds are also useful in combination with androgens, estrogens, progesterones, and antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids, and in contraception, as well as in combination with an angiotensin-converting enzyme inhibitor, an antiotensin  
 20 II-receptor antagonist, or a renin inhibitor for the treatment of uterine fibroids. In addition, the compounds may be used in combination with bisphosphonates and other agents for the treatment and/or prevention of disturbances of calcium, phosphate and bone metabolism, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot  
 25 flashes during therapy with a GnRH antagonist.

The methods of this invention include administering an effective amount of a GnRH receptor antagonist, preferably in the form of a pharmaceutical composition, to a mammal in need thereof. Thus, in still a further embodiment, pharmaceutical compositions are disclosed containing one or more GnRH receptor antagonists of this invention in combination with a pharmaceutically acceptable carrier and/or diluent.

These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain background information, procedures, compounds and/or compositions, and are each hereby incorporated by reference in their entirety.

## 10 DETAILED DESCRIPTION OF THE INVENTION

As mentioned above, the present invention is directed generally to compounds useful as gonadotropin-releasing hormone (GnRH) receptor antagonists. The compounds of this invention have the following structure (I):



(I)

including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof,

wherein:

20  $m$  is an integer from 1 to 6;

$R_1$  is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, aryl( $CR_{3c}R_{3d}$ ) $_n$ , substituted aryl( $CR_{3c}R_{3d}$ ) $_n$ , heteroaryl( $CR_{3c}R_{3d}$ ) $_n$  or substituted heteroaryl( $CR_{3c}R_{3d}$ ) $_n$ ;

25  $R_2$  is hydrogen, alkyl or substituted alkyl;

or  $R_1$  and  $R_2$  taken together with the nitrogen atom to which they are attached form a heterocycle ring or a substituted heterocycle ring;

$R_{3a}$ ,  $R_{3b}$ ,  $R_{3c}$  and  $R_{3d}$  are the same or different and independently at each occurrence hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, thioalkyl, amino, 5 alkylamino, dialkylamino, cyano, halogen,  $-C(=O)OR_7$  or  $-C(=O)NR_7R_8$ ;

or  $R_{3a}$  and  $R_{3b}$ , or  $R_{3c}$  and  $R_{3d}$ , taken together with the carbon atom to which they are attached form a carbocyclic ring or substituted carbocyclic ring;

or  $R_{3a}$  and  $R_1$ , taken together with the carbon atom and nitrogen atom, respectively, to which they are attached form a heterocyclic ring or substituted 10 heterocyclic ring;

$R_4$  is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

$R_5$  is hydrogen, halogen, cyano, alkyl, substituted alkyl, hydroxy, alkoxy, 15 thioalkyl or mono- or di-alkylamine;

$R_6$  is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle,  $-OR_7$ ,  $-SR_7$ ,  $-SOR_7$ ,  $-SO_2R_7$ ,  $-OSO_2R_7$ ,  $-SO_2OR_7$ ,  $-SO_2NR_7R_8$ ,  $-NR_9SO_2R_7$ ,  $-C(=O)R_7$ ,  $-C(=O)OR_7$ ,  $-OC(=O)R_7$ ,  $-NR_7R_8$ ,  $-C(=O)NR_7R_8$ ,  $-OC(=O)NR_7R_8$ ,  $-NR_9C(=O)R_7$ ,  $-NR_9C(=O)NR_7R_8$ ,  $-NR_8C(=O)OR_7$  or  $-C(OH)R_7R_8$ ;

20  $R_7$ ,  $R_8$  and  $R_9$  are the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

or  $R_7$  and  $R_8$  taken together with the nitrogen atom to which they are attached form a heterocycle ring or a substituted heterocycle ring;

25  $n$  is an integer from 1 to 6; and

B and Ar are as follows:

B is nitrogen or  $CR_{10}$  when Ar is heteroaryl or substituted heteroaryl and  $R_{10}$  is hydrogen; or

30 B is  $CR_{10}$  when Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl and  $R_{10}$  is halogen, cyano, nitro, amino, mono- or di-alkylamino or alkyl.

As used herein, the above terms have the following meaning:

“Alkyl” means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon containing from 1 to 8 carbon atoms, while the term “lower alkyl” has the same meaning as alkyl but contains from 1 to 4 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl”, respectively). Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 3-methyl-1 butyne, and the like.

“Aryl” means an aromatic carbocyclic moiety such as phenyl or naphthyl.

“Arylalkyl” means an alkyl having at least one alkyl hydrogen atoms replaced with an aryl moiety, such as benzyl,  $-(CH_2)_2$ phenyl,  $-(CH_2)_3$ phenyl,  $-CH(phenyl)_2$ , and the like.

“Heteroaryl” means an aromatic heterocycle ring of 5- to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and bicyclic ring systems. Representative heteroaryls are pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinoliny, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnoliny, phthalazinyl, and quinazolinyl.



“Heteroarylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heteroaryl moiety, such as -CH<sub>2</sub>pyridinyl, -CH<sub>2</sub>pyrimidinyl, and the like.

“Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-  
5 membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The  
10 heterocycle may be attached via any heteroatom or carbon atom. Heterocycles include heteroaryls as defined above. Thus, in addition to the heteroaryls listed above, heterocycles also include morpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranlyl, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranlyl,  
15 tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranlyl, and the like.

“Heterocyclealkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heterocycle, such as -CH<sub>2</sub>morpholinyl, and the like.

The term “substituted” as used herein means any of the above groups (*i.e.*, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle and heterocyclealkyl)  
20 wherein at least one hydrogen atom is replaced with a substituent. In the case of a keto substituent (“C(=O)”) two hydrogen atoms are replaced. Substituents include halogen, hydroxy, alkyl, haloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -NR'R'', -NR'''C(=O)R', -NR'''C(=O)NR'R'', -NR'''C(=O)OR', -NR'''SO<sub>2</sub>R', -C(=O)R',  
25 -C(=O)OR', -C(=O)NR'R'', -OC(=O)R', -OC(=O)OR', -OC(=O)NR'R'' or -NR'''SO<sub>2</sub>R', wherein R' and R'' are the same or different and independently hydrogen, amino, alkyl, halogenated alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl, or wherein R' and R'' taken together with the nitrogen atom to which they are attached  
30 form a heterocycle or substituted heterocycle.

“Halogen” means fluoro, chloro, bromo and iodo.

"Haloalkyl" means an alkyl having at least one hydrogen atom replaced with halogen, such as trifluoromethyl and the like.

"Alkoxy" means an alkyl moiety attached through an oxygen bridge (*i.e.*, -O-alkyl) such as methoxy, ethoxy, and the like.

5 "Aryloxy" means an aryl moiety attached through an oxygen bridge (*i.e.*, -O-alkyl) such as phenoxy and the like.

"Thiol" means -SH.

"Thioalkyl" means an alkyl moiety attached through a sulfur bridge (*i.e.*, -S-alkyl) such as -SCH<sub>3</sub>, -SCH<sub>2</sub>CH<sub>3</sub> and the like.


10 "Thioaryl" means an aryl moiety attached through a sulfur bridge (*i.e.*, -S-aryl) such as -S-phenyl and the like.

"Mono- or dialkylamine" means -NH(alkyl) or -N(alkyl)(alkyl), respectively.


"Sulfonylalkyl" means an alkyl moiety attached through a sulfonyl  
15 bridge (*i.e.*, -SO<sub>2</sub>-alkyl) such as -SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> and the like.

"Sulfonylaryl" means an aryl moiety attached through a sulfonyl bridge (*i.e.*, -SO<sub>2</sub>-aryl) such as -SO<sub>2</sub>-phenyl and the like.

Depending upon the choice of the B moiety of structure (I), compounds of this invention have the following structure (II) when B is nitrogen, and the following  
20 structure (III) when B is CR<sub>10</sub>:



(II)




(III)

25 In structure (II), Ar is heteroaryl or substituted heteroaryl. Similarly, when R<sub>10</sub> is hydrogen in structure (III), Ar is heteroaryl or substituted heteroaryl.

However, when  $R_{10}$  of structure (III) is halogen, cyano, nitro, amino, mono- or di-alkylamino or alkyl, Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

In one embodiment,  $R_6$  is  $-C(=O)OR_7$ , and representative compounds of this invention have the following structure (IV):


5



(IV)

In another embodiment,  $R_6$  is  $-C(=O)NR_7R_8$ , and representative compounds of this invention have the following structure (V):


10




(V)

In other embodiments,  $R_6$  is  $-C(=O)R_7$ ,  $-C(OH)R_7R_8$  or  $-OR_7$ , and representative compounds of this invention have the following structures (VI), (VII) and (VIII), respectively:


15



(VI)




(VII)




(VIII)


5 In still further embodiments,  $R_6$  is hydrogen, alkyl, substituted alkyl, hydroxy, thioalkyl or sulfonylalkyl, and representative compounds of this invention have the following structures (IX) through (XIV), respectively:




(IX)




(X)




(XI)



(XII)




(XIII)




(XIV)

15 In one embodiment of structure (I),  $R_1$  and  $R_2$ , taken together with the nitrogen atom to which they are attached, form a heterocycle ring as presented by the following structures (XV):




(XV)

Similarly, in more specific embodiments of structure (V),  $R_7$  and  $R_8$ ,  
 5 taken together with the nitrogen atom to which they are attached, form a heterocycle  
 ring or substituted heterocycle ring as represented by the following structure (XVI),  
 optionally in combination with  $R_1$  and  $R_2$  forming a heterocycle ring or substituted  
 heterocycle ring as represented by the following structure (XVII):




(XVI)



(XVII)


In another embodiment of structure (I),  $R_1$  is heteroaryl( $CR_{3c}R_{3d}$ )<sub>n</sub> or  
 substituted heteroaryl( $CR_{3c}R_{3d}$ )<sub>n</sub>. In one aspect of this embodiment, the heteroaryl  
 15 portion of the heteroaryl( $CR_{3c}R_{3d}$ )<sub>n</sub> moiety is pyridinyl (*e.g.*, pyridin-2-yl), and the  
 compounds of this invention have the following structure (XVIII):



(XVIII)

wherein  $R_e$  and  $R_f$  are the same or different and represent optional substituents.  
 5 independently selected from hydrogen, alkyl, alkoxy, dialkylamino, halo and cyano.

In still a further embodiment of structure (I), the  $(CR_{3a}R_{3b})_m$  moiety is an alkylidene moiety, as represented by the following structure (XIX):




(XIX)

10

wherein alkylidene means a bivalent alkyl radical, including bivalent straight chain alkyls such as methylene (*i.e.*,  $-\text{CH}_2-$ ), ethylene (*i.e.*,  $-\text{CH}_2\text{CH}_2-$ ), and the like, bivalent branched alkyls such as  $-\text{CH}(\text{CH}_3)-$ ,  $-\text{C}(\text{CH}_3)_2-$ , and the like, and bivalent cycloalkyls  
 15 such as cyclohexylene, and the like.

In more specific embodiments of this invention, the Ar moiety is a heteroaryl moiety, as represented by the following structure (XX):



(XX)

wherein


5           A<sub>1</sub>, A<sub>3</sub> and A<sub>4</sub> are the same or different and independently nitrogen or CH;



A<sub>2</sub> is oxygen, sulfur, NH, N=N or N=CH; and.

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub> and R<sub>d</sub> are optional substituents that are the same or different and independently halogen, nitro, cyano, alkyl, substituted alkyl, aryl, substituted aryl,  
 10 arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, hydroxy, alkoxy, aryloxy, thiol, thioalkyl, thioaryl, sulfonylalkyl, sulfonylaryl, amino, mono- or di-alkylamino, mono- or di-arylamino, -COOalkyl, -COOaryl, -CONHalkyl, -CONHaryl, -CON(alkyl)<sub>2</sub>, -CON(aryl)<sub>2</sub>, -NHCOalkyl, -NHCOaryl, -N(alkyl)COalkyl, -N(alkyl)COaryl, -NHSO<sub>2</sub>alkyl,  
 15 -NHSO<sub>2</sub>aryl, N(alkyl)SO<sub>2</sub>alkyl, -N(alkyl)SO<sub>2</sub>aryl, -NHCONHalkyl or -NHCONHaryl;



or R<sub>a</sub> and R<sub>b</sub> taken together with the atoms to which they are attached form aryl, substituted aryl, heteroaryl or substituted heteroaryl.

Accordingly, depending upon the choice of A<sub>1</sub>, A<sub>2</sub>, A<sub>3</sub> and A<sub>4</sub> in structure (XX), the heterocyclic ring containing A<sub>1</sub>, A<sub>2</sub>, A<sub>3</sub> and A<sub>4</sub> includes the  
 20 following heteroaryls:






5



10




In addition to the above heteroaryls, this invention also includes heteroaryls wherein  $R_a$  and  $R_b$  taken together with the atoms to which they are attached form aryl or heteroaryl, including (but not limited to) benzofuranyl, isobenzofuranyl, thionaphthenyl, isothionaphthenyl, indoyl, purinyl, quinolinyl, isoquinolinyl, pyrano[3,4-b]pyrrolyl, indoxaziny, benzoxazolyl, anthranyl, cinnolinyl, quinazolinyl, naphthyridinyl, prido[3,4-b]pyridinyl, pyrido[3,2-b]pyridinyl, pyrido[4,3-b]pyridinyl, and the like.

The compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the



Examples. In general, however, the compounds of structure (II) may be made by the following Reaction Schemes A and B, and the compounds of structure (III) by Reaction Schemes C and D. Reaction Schemes E through M illustrate further synthetic procedures applicable to compounds of structure (I) generally. In the following reaction schemes, all substituents are as defined above unless indicated otherwise.


#### Reaction Scheme A




10

As shown in Reaction Scheme A, imidazolo[1,2-a]pyrimidone (iva) can be prepared from  $\alpha$ -bromoheteroaryl ketone ( $\text{R}=\text{alkyl}$ ). Thus, cyclization of bromoketone (ia) with acetyl guanidine in an appropriate solvent such as dimethylformamide at a temperature of 25-120°C for a period of 1-72 hours to give 2-acetamidoimidazole (iia), which can be hydrolyzed with an acid such as sulfuric acid in an appropriate solvent such as water or ethanol at a temperature of 60-120°C for a period of 2-24 hours to give 2-aminoimidazole (iiiia). 2-Aminoimidazole (iiiia) can be modified by cyclization with substituted acrylate in an inert solvent such as methanol, dioxane or phenylether at a temperature of 60-260°C for a period of 0.5-16 hours to give imidazolo[1,2-a]pyrimidone (iva).


20

Reaction Scheme B

- 5 Alternatively, imidazolo[1,2-a]pyrimidone (iva) may be prepared according to Reaction Scheme B by condensation of 2-aminopyrimidine (viia) with the  $\alpha$ -bromoheteroaryl ketone (ia) in the presence of a base such as sodium hydride, tetrabutylammonium fluoride, potassium carbonate in an inert solvent such as DME, dimethylformamide, ethanol at a temperature of 25-100°C for a period of 12-24 hours.

Reaction Scheme C

- 5 In Reaction Scheme C, cyclization of amidine hydrochloride (ib) with a bis-electrophilic reagent, such as diethyl ethoxymethylene malonate in an organic solvent such as ethanol, in the presence of sodium ethoxide at a temperature of 25-100°C, preferably at reflux in ethanol, for a period of 2-12 hours, gives the corresponding pyrimidone (iib). The pyrimidone (iib) may be alkylated by treatment
- 10 with a base such as tetrabutylammonium fluoride, sodium hydride, or sodium ethoxide in an inert solvent such as 1,2-dimethoxyethane, tetrahydrofuran, or mixtures thereof at 0-25°C for a period of 30 minutes, followed by an  $\alpha$ -bromoketone at 0-25°C for 12-24 hours to provide the alkylated pyrimidone (iiib). The pyrimidone (iiib) may be cyclized upon treatment with a strong base such as sodium ethoxide, sodium hydride or
- 15  $LiN(SiMe_3)_2$  in an inert solvent such as ethanol at 25-80°C for 2-4 hours to give the pyrrolo[1,2-a]pyrimidone (ivb).


Reaction Scheme D

- 5 In Reaction Scheme D, heteroaryl ketone (vb) is modified by treatment with a brominating reagent such as copper(II) bromide, bromine, or the like in an organic solvent such as chloroform, ethyl acetate, ether or mixture thereof at a temperature of 25-100°C, preferably at reflux in a mixture of chloroform and ethyl acetate, for a period of 2-12 hours gives the corresponding  $\alpha$ -bromoketone (vib).
- 10 Alternatively, heteroaryl ketone (vb) may be treated with N-bromosuccinamide, or bromine in an inert solvent such as carbon tetrachloride or chloroform with a radical initiator such as AIBN, at reflux to give the bromoketone (vib). The bromoketone (vib) is substituted by treatment with a azide salt such sodium azide, potassium azide or the like in an inert solvent such as DMF, tetrahydrofuran, ether, water or mixture thereof at
- 15 0-50°C for a period of 2-12 hours. The azido group is converted to an amino group when it is dissolved in an appropriate solvent, such a ethanol or methanol with hydrochloric acid, and (a) to the solution is added palladium-carbon or Raney Nickel as the catalyst and the mixture is reacted at room temperature for one to 12 hours under hydrogen atmosphere, or (b) to the solution is added triethyl phosphite and the mixture


is reacted at 0-25°C for 1-24 hours to provide the amino ketone hydrochloride (viib). The amino ketone (viib) is cyclized with malononitrile upon treatment with a strong base such as sodium hydroxide or potassium hydroxide in an inert solvent such as acetonitrile, water, ethanol or mixture thereof at 25-100°C for 2-24 hours to give the aminopyrrole (viiiib). The aminopyrrole (viiiib) is condensed with a biselectrophilic reagent such as diethyl ethoxymethylenemalonate in an inert solvent such as ethanol or dioxane at a temperature of 25-100°C for 12-24 hours, then cyclized in a high boiling solvent such as phenyl ether at 200-265°C for 0.5 -2 hours to provide pyrrolo[1,2-a]pyrimidone (ixb).

10


#### Reaction Scheme E



As shown in Reaction Scheme E, intermediate (ix) can be modified by treatment with an alkyl halide in the presence of a base such as tetrabutylammonium fluoride, sodium hydride or silver(I) oxide in an inert solvent such as DMF, DME, THF or the like at 25-80°C for a period of 1-72 hours to give the corresponding 4-substituted intermediate (x). Alternatively, compound (x) can also be prepared by a Mitsunobu coupling reaction of the starting material (ix) with an alcohol and a coupling reagent such as a mixture of diethyl azodicarboxylate and triphenylphosphine in an inert solvent such as tetrahydrofuran, benzene or ether at a temperature of 0-100°C for 1-24 hours.


Reaction Scheme F

- 5 As shown in Reaction Scheme F, intermediate (x) (R is an alkyl group) can be modified by treatment with a brominating reagent such as N-bromosuccinamide, in the presence of a radical initiator such as AIBN or benzoyl peroxide, in an inert solvent such as carbon tetrachloride, chloroform at temperature ranging from 25 to 100°C for a period of 1-24 hours to give the corresponding
- 10 bromoalkyl intermediate (xi)m which is reacted with a primary or secondary amine (1-5 eq) at a temperature ranging from 0 to 50°C for a period of 0.5 to 16 hours to give compound (xii). The reaction can be carried out under stirring in an appropriate solvent such as dimethylformamide, acetonitrile, ethanol, tetrahydrofuran, chloroform or carbon tetrachloride. In this reaction, if necessary, a base such triethylamine, DBU or pyridine
- 15 may be used.

Reaction Scheme G

5 As shown in Reaction Scheme G, intermediate (xa) can be modified by treatment with an amine such as alkylamine or dialkylamine and an aldehyde such as formaldehyde, paraformaldehyde or acetaldehyde in an appropriate solvent such as ethanol, chloroform, dioxane, acetic acid, or acetonitrile, at a temperature of 25-100°C for a period of 0.5-16 hours to give the amine analog (xiiia).

10


Reaction Scheme H

15 As shown in Reaction Scheme H, the ethyl ester of intermediate (xiii) can be converted to another ester (xiv) by treatment with an excess of alcohol (R<sub>7</sub>OH) and a strong base such as butyllithium, LiN(SiMe<sub>3</sub>)<sub>2</sub>, LDA or potassium t-butoxide with or without an inert solvent such as dioxane, tetrahydrofuran or dimethylformamide, at a temperature of 25-100°C for a period of 0.5-16 hours. The ethyl ester group of compound (xiii) can also be converted to an amide group by dissolving the starting

20

material in an appropriate solvent (*e.g.*, dichloromethane or dichloroethane) and adding to a mixture of a primary or secondary amine ( $R_7R_8NH$ ) and triethylaluminum or dibutylaluminum hydride, and the mixture reacted at 20-100°C for 1-12 hours under nitrogen atmosphere to give amide analog (xv). The ester group of compound (xiii) can also be converted to ketone (xvi) when the starting material is reacted with an appropriate organometallic reagent such as alkyl lithium ( $R_7Li$ ), alkylmagnesiumhalide or organozinc, in an inert solvent such as tetrahydrofuran, ether, hexanes or mixture thereof at a temperature of 0-25°C for a period of 1-16 hours. Furthermore, when more organometallic reagent ( $R_8Li$ ) is used to react with ketone (xvi), the corresponding alcohol (xvii) is obtained.

### Reaction Scheme I




15

As shown in Reaction Scheme I, the ketone derivative of compound (xvi) may be oxidized to provide the carboxylic ester analog (xviii), by treatment with an oxidation reagent such as *m*-chloroperbenzoic acid in an appropriate solvent such as dichloromethane, tetrahydrofuran, ethyl acetate or the like for a period of 1-16 hours or until the starting material has been consumed. The ester (xviii) can be hydrolyzed to the corresponding hydroxy compound (xix) by treatment with a base such as sodium



hydroxide, lithium hydroxide or the like in an appropriate solvent such as ethanol, water, tetrahydrofuran, or mixture thereof at a temperature of 25-100°C for a period of 2-24 hours. The ether derivative (xx) can be prepared by treatment of (xix) with an alkyl halide ( $R_7X$ ) and a base such as potassium carbonate or sodium hydroxide in an  
5 inert organic solvent such as acetone, dimethylformamide or DMSO at a temperature of 25-100°C for a period of 1-72 hours to give product (xx).

## Reaction Scheme J



5

As shown in Reaction Scheme J, the nitro group as the substituent can be converted to an amino group when the starting compound (xxi) is dissolved in an appropriate solvent, (e.g. ethanol or methanol), and (a) to the solution is added a catalyst


such as palladium-carbon or Raney nickel, and the mixture is reacted at room temperature for one to 12 hours under hydrogen atmosphere, or (b) to the solution is added iron powder and hydrochloric acid, and the mixture is reacted at room temperature for one to 12 hours, to give the amino compound (xxii). Mono- or dialkylamino analogs (xxiii and xxiv) can be prepared by reductive amination of amino compound (xxii) with an aldehyde and a reducing agent such as sodium cyanoborohydride, sodium borohydride in an appropriate solvent such as acetic acid, ethanol, acetonitrile, water or mixture thereof at a temperature of 0-100°C for a period of 1-24 hours. Alternatively, (xxiii) and (xxiv) can be prepared by treatment of (xxii) with an alkyl halide and a base such as sodium hydride, potassium carbonate or sodium methoxide in an inert solvent such as tetrahydrofuran, dimethylformamide or DMSO for a temperature of 25-100°C for a period of 2-24 hours.

Urea derivatives (xxv) can be prepared by treatment of amine (xxii) with carbamoyl chloride ( $R'YCOX$ ,  $Y=NR''$ ,  $X=Cl$ ), or alternatively with an isocyanate reagent, and an amine base, such as pyridine, triethylamine, diisopropylethylamine, N-methylmorpholine or the like, in an inert solvent, such as dichloromethane, chloroform, tetrahydrofuran or mixture thereof at a temperature of 0-65°C for a period of 1-72 hours. Compound (xxii) can also be modified by treatment with a bis(electrophilic) reagent such as phosgene, triphosgene, 1,1'-carbonyldiimidazole, N,N'-disuccinimidyl carbonate, or the like with or without the addition of an amine base such as pyridine, triethylamine, diisopropylethylamine, N-methylmorpholine in an inert solvent such as dichloromethane, chloroform, tetrahydrofuran, or the like at a temperature of -20 to 0°C for a period of 0.5-16 hours. After this time, the reaction mixture is treated with an appropriate mono- or disubstituted amine at -20 to 25°C for a period of 1-16 hours to give the urea analog (xxv).

The amino analog (xxii) can also be modified by acylation under a variety of conditions. For example, treatment of (xxii) with an acid chloride ( $R'YCOX$ ,  $Y=CH_2$ ,  $X=Cl$ ), acid anhydride, active ester, or alkyl chloroformate ( $R'YCOX$ ,  $Y=O$ ,  $X=Cl$ ) and an amine base such as triethylamine, diisopropylethylamine, pyridine, or the like in an inert solvent such as dichloromethane, chloroform, tetrahydrofuran, ethyl acetate, or mixture thereof at 0°C to room temperature for a period of one to 12 hours

gives the corresponding amide/urethane derivative (xxv). Alternatively (xxii) may be coupled with carboxylic acid promoted by a dehydrating reagent such as 1,3-dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), with or without a tertiary amine base such as pyridine or  
5 diisopropylethylamine in an inert solvent such as dichloromethane, chloroform, demethylformamide, or the like at room temperature for a period of 2-24 hours to provides the corresponding amide (xxv).

The amino compound (xxii) can also be modified by treatment with appropriate sulfonyl chloride or sulfamyl chloride with an amine base such as pyridine  
10 or triethylamine in an inert solvent such as dichloromethane, chloroform or tetrahydrofuran at a temperature of  $-20$  to  $25^{\circ}\text{C}$  for a period of 0.5 to 12 hours to give the corresponding N-sulfonamide or N-sulfamylamide derivatives (xxvi).


Reaction Scheme K

- 5 As shown in reaction Scheme K, the benzyloxy analog (xxvii) can be converted to the hydroxy compound (xxviii) by treatment with a catalyst such as palladium-carbon or Raney nickel in an inert solvent such as ethanol, methanol or ethyl acetate, on mixture thereof under hydrogen atmosphere at room temperature for a period of 1-24 hours. The hydroxy compound (xxviii) can be further modified to another
- 10 analog (xxix) by treatment with an acid chloride, acid anhydride, alkyl chloroformate, mono-alkyl or dialkylamino carbonyl chloride and an amine base such as triethylamine, pyridine, or N-methylmorpholine in an inert solvent such as dichloromethane, chloroform, ethyl acetate, or tetrahydrofuran at 0 to 65°C for a period of 1-12 hours to give (xxix). The hydroxy compound (xxviii) can also be modified to ether (xxx) by
- 15 treatment with an alkyl or substituted halide and a base such as potassium carbonate in


an inert solvent such as acetone, acetonitrile, or dimethylformamide at 25-100°C for a period of 12-72 hours.

### Reaction Scheme L



5



As shown in Scheme L the ethyl ester (xxxi) can be hydrolyzed to the  
 10 corresponding acid analog (xxxii) by treatment of the ester (xxxi) with a base such as  
 sodium hydroxide, lithium hydroxide or potassium carbonate in an aqueous solvent  
 such as ethanol, methanol, tetrahydrofuran, water or mixture thereof at 0-100°C for 1-24  
 hours. The acid (xxxii) can be modified by treatment with diethyl azido phosphate  
 (DPPA) and a base such as triethylamine in the presence of an alcohol (R<sub>7</sub>OH) in an  
 15 inert solvent such as toluene, dioxane or dimethylformamide at a temperature of 25-  
 120°C for a period of 1-24 hours to give the carbamate (xxxiii).

Reaction Scheme M

5



10

As shown in Reaction Scheme M, compounds of structure (II) may be made by conversion of the appropriate acetoheteroaryl to bromoacetal (xxxiv), which is then reacted with 2-amino-5-bromo-6-methylpyrimidin-4-ol (xxxv) to give the corresponding imidazolopyrimidin-4-one (xxxvi). Compound (xxxvi) is then converted to the R<sub>4</sub>-substituted compound (xxxvii) followed by R<sub>6</sub>-substituted compound (xxxviii), which is then utilized to form compound (xxxvix). This reaction may also be

employed for compounds of structure (III), after formation of the corresponding intermediate (xxxvi) via Reaction Scheme C.

Representative GnRH receptor antagonists of this invention include the following compounds (a) through (p):

5

- (a) 2-(2,5-Dimethylfuran-3-yl)-3-[N-methyl-(2-pyridylethyl)]aminomethyl-5-(3-pentoxycarbonyl)-7-(2-fluorobenzyl)imidazolo[1,2-a]pyrimid-4-one;
- (b) 2-(1-Methylpyrrol-3-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;
- (c) 2-(Thiophen-2-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;
- (d) 2-(2,5-Dimethylfur-3-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;
- (e) 2-(Pyrid-3-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;
- (f) (1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(2,5-dimethylfuran-3-yl)-4-(2-fluorobenzyl)-6-(3-pentoxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one;
- (g) 1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;
- (h) 1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

10

15

20

25



- 5
- (i) 1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-cyanobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;
- (j) 1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-methoxybenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;
- (k) 1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2,4-difluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;
- 10 (l) 1-(N-Benzyl-N-methyl)aminomethyl-2-(4-isobutoxyphenyl)-3-cyano-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;
- (m) 1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(2,5-dimethylfuran-3-yl)-4-(2-fluorobenzyl)-6-(3-pentoxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one;
- 15 (n) 1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(2,5-dimethylfuran-3-yl)-4-(2-fluorobenzyl)-6-(3-pentoxycarbonyl)imidazolo[1,2-a]pyrimid-7-one;
- (o) 1-(N-Benzyl-N-methyl)aminomethyl-2-(4-isobutoxyphenyl)-3-fluoro-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one; and
- 20 (p) 1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(4-isobutoxyphenyl)-3-fluoro-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one.
- 25

The compounds of the present invention may generally be utilized as the free base. Alternatively, the compounds of this invention may be used in the form of acid addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric,

30

gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Thus, the term "pharmaceutically acceptable salt" of structure (I) is intended to encompass any and all acceptable salt forms.

5           In addition, prodrugs are also included within the context of this invention. Prodrugs are any covalently bonded carriers that release a compound of structure (I) *in vivo* when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or *in vivo*, yielding the parent compound.

10          Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structure (I). Further, in the

15          case of an carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like.

          With regard to stereoisomers, the compounds of structure (I) may have chiral centers and may occur as recemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present

20          invention, including mixtures thereof. Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention. In addition, some of the compounds of structure (I) may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.

25           The effectiveness of a compound as a GnRH receptor antagonist may be determined by various assay methods. Suitable GnRH antagonists of this invention are capable of inhibiting the specific binding of GnRH to its receptor and antagonizing activities associated with GnRH. For example, inhibition of GnRH stimulated LH release in immature rats may be measured according to the method of Vilchez-Martinez

30          (*Endocrinology* 96:1130-1134, 1975). Briefly, twenty-five day old male Sprague-Dawley rats are administered an GnRH antagonist in saline or other suitable

formulation by oral gavage, sub-cutaneous injection, or intravenous injection. This is followed by sub-cutaneous injection of 200 ng GnRH in 0.2 mL saline. Thirty minutes after the last injection, the animals are decapitated and trunk blood collected. After centrifugation, the separated plasma is stored at -200°C until determination of the LH and FSH by radioimmunoassay. Other techniques for determining the activity of GnRH receptor antagonists are well known in the field, such as the use of cultured pituitary cells for measuring GnRH activity (Vale et al., *Endocrinology* 91:562-572, 1972), and a technique for measuring radioligand binding to rat pituitary membranes (Perrin et al., *Mol. Pharmacol.* 23:44-51, 1983).

Activity of GnRH receptor antagonists are typically calculated from the  $IC_{50}$  as the concentration of a compound necessary to displace 50% of the radiolabeled ligand from the GnRH receptor, and is reported as a " $K_i$ " value calculated by the following equation:

$$K_i = \frac{IC_{50}}{1 + L / K_D}$$

where L = radioligand and  $K_D$  = affinity of radioligand for receptor (Cheng and Prusoff, *Biochem. Pharmacol.* 22:3099, 1973). GnRH receptor antagonists of this invention have a  $K_i$  of 10  $\mu$ M or less. In a preferred embodiment of this invention, the GnRH receptor antagonists have a  $K_i$  of less than 1  $\mu$ M, and more preferably less than 100 nM.

The compounds of this invention are more resistant to metabolic enzymes, provide increased bioavailability and longer duration of action, are better absorbed, are more potent, and/or have enhanced solubility properties compared to existing GnRH receptor antagonists. As GnRH receptor antagonists, the compounds of this invention have utility over a wide range of therapeutic applications, and may be used to treat a variety of sex-hormone related conditions in both men and women, as well as mammals in general. For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual

syndrome, benign prostatic hypertrophy, contraception and infertility (*e.g.*, assisted reproductive therapy such as *in vitro* fertilization).

The compounds of this invention are also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of  
5 systemic lupus erythematosus.

In addition, the compounds are useful in combination with androgens, estrogens, progesterones, and antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids, and in contraception, as well as in combination with an angiotensin-converting enzyme inhibitor, an antiotensin II-receptor antagonist, or a  
10 renin inhibitor for the treatment of uterine fibroids. The compounds may also be used in combination with bisphosphonates and other agents for the treatment and/or prevention of disturbances of calcium, phosphate and bone metabolism, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy  
15 with a GnRH antagonist.

In another embodiment of the invention, pharmaceutical compositions containing one or more GnRH receptor antagonists are disclosed. For the purposes of administration, the compounds of the present invention may be formulated as pharmaceutical compositions. Pharmaceutical compositions of the present invention  
20 comprise a GnRH receptor antagonist of the present invention and a pharmaceutically acceptable carrier and/or diluent. The GnRH receptor antagonist is present in the composition in an amount which is effective to treat a particular disorder--that is, in an amount sufficient to achieve GnRH receptor antagonist activity, and preferably with acceptable toxicity to the patient. Typically, the pharmaceutical compositions of the  
25 present invention may include a GnRH receptor antagonist in an amount from 0.1 mg to 250 mg per dosage depending upon the route of administration, and more typically from 1 mg to 60 mg. Appropriate concentrations and dosages can be readily determined by one skilled in the art.

Pharmaceutically acceptable carrier and/or diluents are familiar to those  
30 skilled in the art. For compositions formulated as liquid solutions, acceptable carriers and/or diluents include saline and sterile water, and may optionally include antioxidants,

buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a GnRH receptor antagonist, diluents, dispersing and surface active agents, binders, and lubricants. One skilled in this art may further formulate the GnRH receptor antagonist  
5 in an appropriate manner, and in accordance with accepted practices, such as those disclosed in *Remington's Pharmaceutical Sciences*, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.

In another embodiment, the present invention provides a method for treating sex-hormone related conditions as discussed above. Such methods include  
10 administering of a compound of the present invention to a warm-blooded animal in an amount sufficient to treat the condition. In this context, "treat" includes prophylactic administration. Such methods include systemic administration of a GnRH receptor antagonist of this invention, preferably in the form of a pharmaceutical composition as discussed above. As used herein, systemic administration includes oral and parenteral  
15 methods of administration. For oral administration, suitable pharmaceutical compositions of GnRH receptor antagonists include powders, granules, pills, tablets, and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives. For parental  
20 administration, the compounds of the present invention can be prepared in aqueous injection solutions which may contain, in addition to the GnRH receptor antagonist, buffers, antioxidants, bacteriostats, and other additives commonly employed in such solutions.

The compounds of this invention may be evaluated as GnRH receptor  
25 antagonists according to the following techniques.

#### Rat Anterior Pituitary Cell Culture Assay of GnRH Antagonists

Anterior pituitary glands are collected from 7-week-old female Sprague-Dawley rats and the harvested glands digested with collagenase in a dispersion flask for  
30 1.5 hr at 37°C. After collagenase digestion, the glands are further digested with neuraminidase for 9 min at 37°C. The digested tissue is then washed with 0.1%

BSA/McCoy's 5A medium, and the washed cells suspended in 3% FBS/0.1 BSA/McCoy's 5A medium and plated into 96-well tissue culture plates at a cell density of 40,000 cells per well in 200  $\mu$ l medium. The cells are then incubated at 37°C for 3 days. One pituitary gland normally yields one 96-well plate of cells, which can be used  
5 for assaying three compounds. For assay of an GnRH antagonist, the incubated cells are first washed with 0.1% BSA/McCoy's 5A medium once, followed by addition of the test sample plus 1nM GnRH in 200  $\mu$ l 0.1% BSA/McCoy's 5A medium in triplicate wells. Each sample is assayed at 5-dose levels to generate a dose-response curve for determination of its potency on the inhibition of GnRH stimulated LH and/or FSH  
10 release. After 4-hr incubation at 37°C, the medium is harvested and the level of LH and/or FSH secreted into the medium determined by RIA.

#### RIA of LH and FSH

For determination of the LH levels, each sample medium is assayed in  
15 duplicates and all dilutions are done with RIA buffer (0.01M sodium phosphate buffer/0.15M NaCl/1% BSA/0.01% NaN<sub>3</sub>, pH 7.5) and the assay kit is obtained from the Nation Hormone and Pituitary Program supported by NIDDK. To a 12x75 mm polyethylene test tube is added 100  $\mu$ l of sample medium diluted 1:5 or rLH standard in RIA buffer and 100  $\mu$ l of [125I]-labeled rLH (~30,000 cpm) plus 100  $\mu$ l of rabbit anti-  
20 rLH antibody diluted 1:187,500 and 100  $\mu$ l RIA buffer. The mixture is incubated at room temperature over-night. In the next day, 100  $\mu$ l of goat anti-rabbit IgG diluted 1:20 and 100  $\mu$ l of normal rabbit serum diluted 1:1000 are added and the mixture incubated for another 3 hr at room temperature. The incubated tubes are then centrifuged at 3,000 rpm for 30 min and the supernatant removed by suction. The remaining pellet in the  
25 tubes is counted in a gamma-counter. RIA of FSH is done in a similar fashion as the assay for LH with substitution of the LH antibody by the FSH antibody diluted 1:30,000 and the labeled rLH by the labeled rFSH.

#### Radio-iodination of GnRH Peptide

30 The GnRH analog is labeled by the chloramine-T method. To 10  $\mu$ g of peptide in 20  $\mu$ l of 0.5M sodium phosphate buffer, pH 7.6, is added 1 mCi of Na<sup>125</sup>I,

followed by 22.5 µg chloramine-T and the mixture vortexed for 20 sec. The reaction is stopped by the addition of 60 µg sodium metabisulfite and the free iodine is removed by passing the iodinated mixture through a C-8 Sep-Pak cartridge (Millipore Corp., Milford, MA). The peptide is eluted with a small volume of 80% acetonitrile/water.

- 5 The recovered labeled peptide is further purified by reverse phase HPLC on a Vydac C-18 analytical column (The Separations Group, Hesperia, CA) on a Beckman 334 gradient HPLC system using a gradient of acetonitrile in 0.1% TFA. The purified radioactive peptide is stored in 0.1% BSA/20% acetonitrile/0.1% TFA at -80°C and can be used for up to 4 weeks.

10

#### GnRH Receptor Membrane Binding Assay

- Cells stably, or transiently, transfected with GnRH receptor expression vectors are harvested, resuspended in 5% sucrose and homogenized using a polytron homogenizer (2x15 sec). Nuclei are removed by centrifugation (3000 x g for 5 min.), and the supernatant centrifuged (20,000 x g for 30 min, 4°C) to collect the membrane fraction. The final membrane preparation is resuspended in binding buffer (10mM Hepes (pH 7.5), 150 mM NaCl, and 0.1% BSA) and stored at -70°C. Binding reactions are performed in a Millipore MultiScreen 96-well filtration plate assembly with polyethylenimine coated GF/C membranes. The reaction is initiated by adding
- 20 membranes (40 ug protein in 130 ul binding buffer) to 50ul of [<sup>125</sup>I]-labeled GnRH peptide (~100,000 cpm), and 20ul of competitor at varying concentrations. The reaction is terminated after 90 minutes by application of vacuum and washing (2X) with phosphate buffered saline. Bound radioactivity is measured using 96-well scintillation counting (Packard Topcount) or by removing the filters from the plate and direct
- 25 gamma counting. K<sub>i</sub> values are calculated from competition binding data using non-linear least squares regression using the Prism software package (GraphPad Software).

The following examples are provided for purposes of illustration, not limitation.


## EXAMPLES

In summary, the following Examples disclose the synthesis of representative compounds of this invention. Such compounds may be evaluated for activity as GnRH receptor antagonists according to the methods set forth above.

5

EXAMPLES 1-20

3-CYANO-6-(3-ETHOXYCARBONYL)-4-(2-FLUOROBENZYL)-  
2-(4-METHOXYPHENYL)-1-METHYLPYRROLO[1,2-A]PYRIMID-7-ONE



10

1

Step A 4'-Methoxy-2-bromopropiophenone

To a flask containing a mixture of  $\text{CHCl}_3$  (200 mL) and ethyl acetate (200 mL), 4'-methoxypropiophenone (32.8 g, 0.2 mole) was added, followed by addition of copper(II) bromide (89.4 g, 0.4 mole) in several portions. The mixture was then refluxed for 1 hour and stirred at room temperature overnight. The solids were filtered and washed with ethyl acetate (2x100 mL). The filtrated solution was then washed with water (2x100 mL) and dried over  $\text{Na}_2\text{SO}_4$ . Concentration gave a brown oil which was then dissolved in ether (300 mL) and stored at  $0^\circ\text{C}$  for 1 day. The crystals formed and were filtered and washed with a mixture of ether/hexane (1:1, 2x100 mL), air-dried to give the titled compound (35.5g, 73 %); proton NMR ( $\text{CDCl}_3$ )  $\delta$ : 8.02 (2H,d,  $J=9\text{Hz}$ ), 6.95 (2H,d,  $J=9\text{Hz}$ ), 5.27 (1H,q,  $J=6.6\text{Hz}$ ), 3.88 (3H, s), 1.89(3H,d,  $J=6.6\text{Hz}$ ).

25

Step B 4'-Methoxy-2-aminopropiophenone hydrochloride

4'-Methoxy-2-bromopropiophenone (10 g, 41 mmol.) was dissolved in a mixture of THF (100 mL) and water (20 mL), followed by addition of sodium azide (6.5



g, 0.1 mole). The slurry was vigorously stirred for 5 hours and TLC indicated a completed conversion to 4'-methoxy-2-azidopropiophenone. The aqueous layer was then removed and the organic layer was further diluted with ethanol (200 mL). Concentrated hydrochloride (5 mL, about 60 mmol.) and palladium on carbon (10%, 2 g) were added and hydrogenation was performed using Parr apparatus at 20 psi for 1 hour. The product precipitated during the hydrogenation was re-dissolved by addition of methanol (100 mL). After filtration to remove the catalyst, the solution was concentrated to form a solid. It was stirred with ether (300 mL) and solids were filtered and dried under vacuum at 50°C overnight to give the titled compound (8.8 g, 100%) MS: 180 (MH<sup>+</sup>), 162 (M-NH<sub>3</sub>). Proton NMR (DMSO-d<sub>6</sub>) δ: 7.96(2H, brs), 7.79(2H, d, J=8.4Hz), 6.87( 2H, d, J=8.4Hz), 4.49( 1H,brs), 1.17(2H, d, J=6.9Hz).

Step C      3-Cyano-6-ethoxycarbonyl-2-(4-methoxyphenyl)-1-methyl-4H-pyrrolo[1,2-a]pyrimid-7-one

To a refluxing solution (150 mL) of ethanol and water (7/3), NaOH (2.2 g, 55 mmol) and malononitrile ( 2.64 g, 40 mmol) were added. Then 4'-methoxy-2-aminopropiophenone hydrochloride (5.9 g, 27.2 mmol) was added in several portions. After the solution was refluxed for 30 minutes., additional malonitrile (1.3 g, 20 mmol) and NaOH (1.1 g, 27.5 mmol) were added. It was refluxed for additional 30 minutes and then poured into water (100 mL) which resulted in a precipitation. It was then filtered and washed with water until no color was washed out. The solid was then dried under vacuum at 50°C overnight to give 2-amino-3-cyano-4-(4-methoxyphenyl)-5-methylpyrrole, (3.9 g, 63%). MS: 228 (MH<sup>+</sup>).


2-amino-3-cyano-4-(4-methoxyphenyl)-5-methylpyrrole was then refluxed with diethyl ethoxymethylene malonate ( 2.75 g, 12.7 mmol ) in ethanol for 24 hours and concentrated to a deep brown oil. The oil was mixed with Dowtherm (20 mL) and then heated at 240°C for 30 minutes. After cooling down to room temperature, it was diluted with ether (200 mL) resulting in a precipitation. The precipitates were filtered, washed with ether (2x100 mL), and air-dried to give the titled compound as a yellow powder (2.8 g, 63%); proton NMR (DMSO-d<sub>6</sub>) δ: 8.08 (1H, s), 7.09 (2H, d,

J=8.1Hz), 6.84 (2H, d, J=8.1Hz), 3.97 (2H, q, J=6.9Hz), 3.57 (3H, s), 2.36 (s, 3H), 1.03 (3H, t, J=6.9Hz); MS: 352 (MH<sup>+</sup>).

Step D 3-Cyano-6-ethoxycarbonyl-4-(2-fluorobenzyl)-2-(4-methoxyphenyl)-1-methylpyrrolo[1,2-a]pyrimid-7-one

To 3-cyano-6-ethoxycarbonyl-2-(4-methoxyphenyl)-1-methyl-4H-pyrrolo[1,2-a]pyrimid-7-one (351 mg, 1.0 mmol.) in dry DMF (5 mL) under N<sub>2</sub>, 2-fluorobenzyl bromide (473 mg, 2.5 mmol) and silver(I) oxide (924 mg, 4 mmol) were added. The slurry was stirred for 2 days at room temperature and poured into water (10 mL). Crude product was extracted out from water by ethyl acetate (50 mL). The organic layer was then concentrated and purified by silica gel chromatography (ethyl acetate/hexane) to give a pure product. It was crystallized in ether /ethyl acetate to give the titled compound as off white crystals (310 mg, 52%); proton NMR (DMSO-d<sub>6</sub>): 8.67 (1H, s), 7.45-7.80 (6H, m), 7.00 (2H, d, J=7.8Hz), 5.70 (2H, s), 4.18 (2H, q, J=6.6Hz), 3.74 (3H, s), 2.56 (3H, s), 1.23 (3H, t, J=6.6Hz); MS: 460 (MH<sup>+</sup>).

By the above procedures, the following compounds were also prepared:




20

Example	Ar	R <sub>4</sub>	MS (MH <sup>+</sup> )
2	4-MeO-Ph	cycloPrCH <sub>2</sub>	406
3	4-MeO-Ph	PhCH=CHCH <sub>2</sub>	468
4	4-MeO-Ph	Bn	442
5	4-MeO-Ph	2-F-Bn	460
6	4-MeO-Ph	2-MeO-Bn	472
7	4-MeO-Ph	2-NC-Bn	467

Example	Ar	R <sub>4</sub>	MS (MH <sup>+</sup> )
8	4-MeO-Ph	2-Cl-Bn	476
9	4-MeO-Ph	2,3-F-Bn	439
10	4-MeO-Ph	2,4-F-Bn	439
11	4-MeO-Ph	2,6-F-Bn	439
12	4-MeO-Ph	3,5-F-Bn	439
13	4-MeO-Ph	3,5-CF <sub>3</sub> -Bn	478
14	4-iBuO-Ph	2-F-Bn	502
15	4-iBuO-Ph	2-MeO-Bn	514
16	4-iBuO-Ph	2-NC-Bn	509
17	4-iBuO-Ph	2,4-F-Bn	520
18	4-iBuO-Ph	2,5-F-Bn	520
19	4-iBuO-Ph	2,6-F-Bn	520
20	4-Br-Ph	2-F-Bn	508

### EXAMPLES 21-37

3-CYANO-6-ETHOXYCARBONYL-4-(2-FLUOROBENZYL)-2-(4-METHOXYPHENYL)-1-{N-  
 5 METHYL-N-[2-(2-PYRIDYL)ETHYL]AMINOMETHYLPYRROLO[1,2-A]PYRIMID-7-ONE




21

10 To 3-cyano-6-ethoxycarbonyl-4-(2-fluorophenyl)-2-(4-methoxyphenyl)-  
 1-methylpyrrolo[1,2-a]pyrimidone (460 mg, 1.0 mmol) (from Example 1 above) in  
 refluxing CCl<sub>4</sub> (30 mL), NBS (235mg, 1.4mmol) and 3 particles of benzoyl peroxide


were added. It was refluxed for 30 minutes and cooled down to room temperature. Triethylamine (1 mL) and acetonitrile (2 mL) and 2-(N-methylaminoethyl)pyridine were added. It was then stirred at room temperature for 30 minutes. Concentration gave an oil which was purified by prep-TLC plate ( $\text{CHCl}_3/\text{MeOH}/\text{NH}_4\text{OH}=200/50/1$ ),  
 5 producing the titled compound as a pure product (220 mg, 37%). Proton NMR ( $\text{CDCl}_3$ )  $\delta$ : 8.23 (1H, d,  $J=4.5\text{Hz}$ ), 8.19 (1H,s), 7.53-7.11 (9H, m), 6.95 (2H, d,  $J=8.4\text{Hz}$ ), 5.61 (2H, s), 4.34 (2H, q,  $J=7.2\text{Hz}$ ), 4.17 (2H, brs), 3.84 (3H, s), 2.95-2.75 (4H, m), 2.15 (3H, s), 1.34 (3H, t,  $J=7.2\text{Hz}$ ); MS: 594 (MH<sup>+</sup>).

10

By the above procedures, the following compounds were also prepared:




Example	R <sub>1</sub> NR <sub>2</sub>	MS(M+H)
22	BnNMe	579
23	4-pyridylCH <sub>2</sub> NMe	594
24	3,4-Cl-PhCH <sub>2</sub> NMe	662
25	PropargylNMe	527
26	CycloPrCH <sub>2</sub> NPr	571
27	MeNMe	503
28	3-pyridyl(CH <sub>2</sub> ) <sub>4</sub> NMe	622
29	2-pyridyl(CH <sub>2</sub> ) <sub>2</sub> NMe	594
30	6-Me-2-pyridylCH <sub>2</sub> NMe	594
31	2-furfurylCH <sub>2</sub> NMe	569
32	MeOCH <sub>2</sub> CH <sub>2</sub> NMe	547
33	2-pyridylCH <sub>2</sub> NMe	580
34	AllylNMe	529

Example	R <sub>1</sub> NR <sub>2</sub>	MS(M+H)
35	PhCH(OH)CH <sub>2</sub> CH <sub>2</sub> NMe	623
36	BnNCH <sub>2</sub> CH <sub>2</sub> NMe	636
37		635

EXAMPLES 38-47


3-CYANO-6-(3-PENTYLOXYCARBONYL)-4-(2-FLUOROBENZYL)-2-(4-METHOXYPHENYL)-1-  
 5 {N-METHYL-N-[2-(2-PYRIDYL)ETHYL]AMINOMETHYLPYRROLO[1,2-A]PYRIMID-7-ONE



38

10 To 3-cyano-6-ethoxycarbonyl-4-(2-fluorophenyl)-2-(4-methoxyphenyl)-  
 1-{N-methyl-N-[2-(2-pyridyl)ethyl]aminomethyl}pyrrolo[1,2-a]pyrimidinone (59 mg, 0.1  
 mmol) in dry THF (2 mL) under nitrogen atmosphere was added 3-pentanol (0.5 mL)  
 and KN(TMS)<sub>2</sub> in toluene (0.5 M, 3 mL, 1.5 mmol). The mixture was stirred for 30  
 minutes, quenched by ethyl acetate (30 mL) and HCl (2N, 10 mL). The organic layer  
 15 was separated, concentrated and purified by Prep-TLC to give the titled compound (18  
 mg, yield 28%). Proton NMR (CDCl<sub>3</sub>) δ: 8.43 (1H, d, J=5.1Hz), 8.16 (1H, s), 7.54-6.96  
 (9H, m), 6.98 (2H, d, J=8.7Hz), 5.62 (2H, s), 5.00-4.92 (1H, m), 4.12 (2H, s), 3.87 (3H,  
 s), 2.90-2.80 (2H, m), 2.80-2.70 (2H, m), 2.11 (3H, s), 1.70-1.61 (4H, m), 0.92 (6H, t,  
 J=7.2Hz); MS: 636 (MH<sup>+</sup>).


By the above procedure, the following compounds were also prepared:



Example	R <sub>1</sub> NR <sub>2</sub>	R <sub>7</sub>	MS (M+H)
39	2-pyridylCH <sub>2</sub> CH <sub>2</sub> NMe	i-Pr	608
40	PhCH(OH)CH <sub>2</sub> CH <sub>2</sub> NMe	i-Pr	637
41	2-pyridylCH <sub>2</sub> CH <sub>2</sub> NMe	(cycloPr) <sub>2</sub> CH	660
42	2-pyridylCH <sub>2</sub> CH <sub>2</sub> NMe	(Et) <sub>2</sub> CH	636
43	2-pyridylCH <sub>2</sub> CH <sub>2</sub> NMe	H	566
44	2-pyridylCH <sub>2</sub> CH <sub>2</sub> NMe	cyclopentyl	634
45	2-pyridylCH <sub>2</sub> NH	cyclopentyl	606
46	2-pyridylCH <sub>2</sub> CH <sub>2</sub> NMe		636
47	2-PyridylCH <sub>2</sub> CH <sub>2</sub> NMe	(i-Pr) <sub>2</sub> CH	664

EXAMPLES 48-63

The following compounds were made by the procedures set forth in the preceding Examples.




5

Example	R <sub>4</sub>	R <sub>7</sub>	MS(M+1)
48	Bn	Ethyl	576
49	2,6-F-Bn	Ethyl	612
50	2-F-Bn	Ethyl	594
51	PhCH=CHCH <sub>2</sub>	Ethyl	602
52	CycloPrCH <sub>2</sub>	Ethyl	540
53	2-Cl-Bn	Ethyl	610
54	3,5-CF <sub>3</sub> -Bn	Ethyl	712
55	2-MeO-Bn	Ethyl	606
56	2-MeO-Bn	i-Pr	620
57	2-MeO-Bn	3-pentyl	648
58	3,5-F-Bn	Ethyl	612
59	2-F-Bn	(cycloPr) <sub>2</sub> CH	660
60	2-NC-Bn	Ethyl	601
61	2-F-Bn	H	566
62	2,4-F-Bn	Ethyl	612
63	2,3-F-Bn	Ethyl	612

EXAMPLE 64

3-CYANO-6-(3-PENTYLOXYCARBONYL)-  
 4-(2-FLUOROBENZYL)-2-[4-(3-PENTYL)OXYPHENYL]-1-{N-METHYL-N-[2-(2-  
 5 PYRIDYL)ETHYL]AMINOMETHYL}PYRROLO[1,2-A]PYRIMID-7-ONE



64

10 Step A 3-Cyano-6-(3-hydroxycarbonyl)-4-(2-fluorobenzyl)-2-(4-  
hydroxyphenyl)-1-{N-methyl-N-[2-(2-  
pyridyl)ethyl]aminomethyl}pyrrolo[1,2-a]pyrimid-7-one

To a stirred solution of 3-cyano-6-(3-ethoxycarbonyl)-4-(2-  
 fluorobenzyl)-2-(4-methoxyphenyl)-1-methylpyrrolo[1,2-a]pyrimid-7-one (230 mg, 0.5  
 15 mmol) in dry DCM (2 mL) at  $-78^{\circ}\text{C}$  under atmosphere of  $\text{N}_2$ , Boron tribromide (4 mL,  
 1M in DCM) was added dropwise. After completion of the addition, the cooling bath  
 was removed and the mixture was warmed to room temperature and stirred for 5 hours.  
 It was then poured into stirring water (10 mL) resulting in a precipitation. The  
 precipitates were filtered, washed with water (2x20 mL), ether (10 mL), dried to give  
 20 the titled product (150 mg, 72%). MS: 418 ( $\text{MH}^+$ ), 400 ( $\text{M-OH}^+$ ).



Step B      3-Cyano-6-(3-pentoxycarbonyl)-4-(2-fluorobenzyl)-2-[4-(3-pentoxyphenyl)-1-methylpyrrolo[1,2-a]pyrimid-7-one

To a stirred solution of 3-Cyano-6-(3-hydroxycarbonyl)-4-(2-fluorobenzyl)-2-(4-hydroxyphenyl)-1-methylpyrrolo[1,2-a]pyrimid-7-one (83 mg, 0.2 mmol) in dry DMF (5 mL) under atmosphere of N<sub>2</sub>, potassium carbonate (500 mg, 3.6 mmol) was added, followed by addition of 3-bromopentane (0.5 mL, 4.0 mmol). The slurry was heated at 90°C overnight and treated with ethyl acetate (20 mL) and water (20 mL). The organic layer was separated and filtered through a silica gel pad (10 g), washed with ethyl acetate. It was then concentrated to give the titled product, essentially pure by TLC (85 mg, 76%). MS: 558 (MH<sup>+</sup>).


Step C      3-Cyano-6-(3-pentoxycarbonyl)-4-(2-fluorobenzyl)-2-[4-(3-pentoxyphenyl)-1-{N-methyl-N-[2-(2-pyridyl)ethyl]aminomethylpyrrolo[1,2-a]pyrimid-7-one

To a refluxing solution of carbon tetrachloride (5 mL) containing 3-cyano-6-(3-pentoxycarbonyl)-4-(2-fluorobenzyl)-2-[4-(3-pentoxyphenyl)-1-methylpyrrolo[1,2-a]pyrimid-7-one (85 mg, 0.15 mmol), NBS (43 mg, 1.5 eq) and 3 particles of benzoyl peroxide were added in one portion. It was refluxed for 1 hour to give the bromo compound. The solution was then divided into 4 portion equally. To one portion with stirring, 1 drop of 2-(N-methylethyl)pyridine was added. After stirred for 5 minutes, it was purified by prep-TLC plate (CHCl<sub>3</sub>/MeOH/NH<sub>4</sub>OH=500/50/1) to give the pure titled product as an oil (9.0 mg, 35%). NMR (CDCl<sub>3</sub>, δ): 8.42 (1H, d, J=3.9Hz), 8.14 (1H, s), 7.52-6.92 (11H, m), 5.60 (2H, s), 4.96-4.89 (1H, m), 4.16-4.11 (2H, m), 2.90-2.70 (4H, m), 2.13 (3H, s), 1.75-1.59 (8H, m), 1.00-0.87 (12H, m). MS: 678 (MH<sup>+</sup>).

EXAMPLES 65-75

2-(2,5-DIMETHYL-3-FURYL)-3-{N-METHYL-N-[2-(2-PYRIDYL)ETHYL]AMINOMETHYL}-  
5-(3-METHOXYPHENYL)-6-METHYL-  
7-(2-FLUOROPHENYLMETHYL)IMIDAZOLO[1,2-A]-PYRIMID-4-ONE

5



65

Step A 3-(Bromoacetyl)-2,5-dimethylfuran

10 Copper bromide (17.9g, 2.0eq) was added to a solution of the 2,5-dimethyl 3-acetofuran (5.52g, 40 mmol) in EtOAc/CHCl<sub>3</sub> (1:1, 50 mL). The mixture was refluxed for 2.5 hours, at which time the starting material was almost totally consumed. It was then cooled down and filtered to remove the copper residue. The green filtrate was concentrated to yield an oil which was diluted with ether, filtered  
15 again to further remove some black insoluble residue. The filtrate was then concentrated to yield an oil (6.5g) as the desired product, which was directly used in the next step.

Step B 2-(2,5-dimethyl-3-furyl)-5-bromo-6-methylimidazo[1,2-a]pyrimidin-4-one

20

2-amino-5-bromo-6-methylpyrimidin-4-ol (2.04 g, 10 mmol) suspended in DMF was treated with NaH (60%, 520 mg, 1.3eq) carefully. A lot of bubbles were generated. The mixture was stirred at room temperature for 30 minutes. 3-

(Bromoacetyl)-2,5-dimethylfuran dissolved in DMF was added dropwise. The brown solution was stirred at room temperature for 3 hours. It was then dumped into iced 1N HCl. Precipitate generated was filtered and washed with water, ether and dried to yield a solid as the desired product (2.8 g); MS *m/e* 324 (M+H).

5

Step C      2-(2,5-Dimethyl-3-furyl)-5-bromo-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one

2-(2,5-Dimethyl-3-furyl)-6-methylimidazolo[1,2-a]pyrimid-4-one (1 g, 3.1 mmol) was suspended in DME (6 mL), treated with TBAF (1M in THF, 4.65 mL, 1.5 eq) to yield a clear solution, 2-fluorobenzyl bromide was then added. The mixture was stirred at room temperature for 3 hours, the precipitate generated was filtered and washed with water (50 mL), ether (50 mL) to yield a white solid (203 mg); MS: *m/e* 430 (M+H).

15 Step D      2-(2,5-Dimethyl-3-furyl)-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one


2-(2,5-Dimethyl-3-furyl)-5-bromo-6-methyl-7-(2-fluorophenylmethyl)-imidazolo[1,2-a]pyrimid-4-one (200mg, 0.466 mmol) , boronic acid (74 mg, 1.05 eq.), Pd(OAc)<sub>2</sub> (5.2 mg, 0.05eq), PPh<sub>3</sub> (12 mg, 0.1eq), K<sub>2</sub>CO<sub>3</sub> (129mg, 2.0eq) were charged into the reaction flask, degassed and protected under N<sub>2</sub> atmosphere. Toluene (4 mL) and H<sub>2</sub>O (1 mL) were then added. The mixture was refluxed at 110°C for 6 hours. MS indicated about ¼ of the bromide was still remained unchanged. The reaction was stopped by filtering off the Pd catalyst. The filtrate was partitioned between EtOAc and water. The organic layer was concentrated to yield a light yellow solid as the crude product which was directly used in the next step without further purification (200 mg); MS: *m/e* 458 (M+H).

25

Step E 2-(2,5-dimethyl-3-furyl)-3-{N-methyl-N-[2-(2-pyridyl)ethyl]aminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one  
 2-(2,5-Dimethyl-3-furyl)-5-(3-methoxyphenyl)-6-methyl-7-(2-

- 5 fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one (30 mg) obtained above as suspended in acetic acid and treated with 2 drops of amine followed by 2 drops of the formaldehyde (37% water solution). The reaction was stirred at room temperature for 1 hour. HOAc was evaporated and the residue was diluted with DCM and purified by prep-TLC to yield the desired product, which was characterized by proton NMR and
- 10 mass spectra.


Following procedures similar to that described above, the compounds listed below were also prepared.



15

Ex.	$-C(R_{3a}R_{3b})_mNR_1R_2$	MS (M+H)	Proton NMR
65	$-CH_2N(Me)(CH_2CH_2-2-Py)$	606	2.24 (s, 3H), 2.27 (s, 3H), 2.97 (m, 4H), 3.80 (s, 3H), 4.11 (s, 2H), 5.62 (s, 2H), 6.08 (s, 1H), 6.80-7.58 (m, 11H), 8.41 (m, 1H)
66	$-CH_2N(Me)(Bn)$	591	2.18 (s, 3H), 3.24 (s, 3H), 3.40 (s, 3H), 3.61 (s, 2H), 3.82 (s, 2H), 4.13 (s, 2H), 5.64 (s, 2H), 6.31 (s, 1H), 6.80-7.39 (m, 13H)


Ex.	$-\text{C}(\text{R}_{3a}\text{R}_{3b})_m\text{NR}_1\text{R}_2$	MS (M+H)	Proton NMR
67	$-\text{CH}_2\text{N}(\text{Me})(\text{CH}_2\text{CH}_2\text{NEt}_2)$	600	---
68	$-\text{CH}_2\text{N}(\text{Me})(\text{CH}_2\text{CH}_2\text{OMe})$	559	---



Ex.	R <sub>1</sub>	R <sub>6</sub>	MS (M+H)
69	-Bn	3-EtOPh	605
70	$-\text{CH}_2\text{CH}_2\text{-2-Py}$	3-EtOPh	620
71	-Bn	3-FPh	579
72	$-\text{CH}_2\text{CH}_2\text{-2-Py}$	3-FPh	594
73	-Bn	3-Py	562
74	$-\text{CH}_2\text{CH}_2\text{-2-Py}$	3-Py	577
75	$-\text{CH}_2\text{CH}_2\text{NMe}_2$	3-Py	543

EXAMPLES 76-77

2-(2,5-DIMETHYL-3-FURYL)-1-{N-METHYL-N-[2-(2-PYRIDYL)ETHYL]AMINOMETHYL}-6-ETHOXYCARBONYL-4-(2-FLUOROPHENYLMETHYL)PYRROLO[1,2-A]PYRIMID-7-ONE



76

Step A. 1-[2-(2,5-Dimethyl-3-furyl)-2-oxoethyl]-2-methyl-5-ethoxycarbonylpyrimid-6-one

5-Ethoxycarbonyl-2-methylpyrimid-4-one (3.5g, 19 mmol) was dissolved in DME (110 mL) and TBAF (28.5 mL, 1 M solution in THF, 28.5 mmol) added dropwise at 0°C. The resulting solution was stirred ten minutes and a solution of 3-bromoacetyl-2,5-dimethylfuran (4.3 g, 20 mmol) in DME (10 mL) was added dropwise. The reaction was stirred at room temperature overnight. The solution was then concentrated *in vacuo* and partitioned between EtOAc and saturated aqueous NH<sub>4</sub>Cl. The EtOAc layer was separated and concentrated. The product was purified using flash silica chromatography (EtOAc/hexane = 2:8 to 8:2), with the o-alkylated side product eluting at 4:6, and the desired N-alkylated product eluting at 8:2. The N-alkylated product was dried as a yellow solid, isolated in 31% yield; MS: 319 (M+H) and 273.

Step B. 2-(2,5-Dimethyl-3-furyl)-4H-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one

1-[2-(2,5-Dimethyl-3-furyl)-2-oxoethyl]-2-methyl-5-ethoxycarbonyl-pyrimid-6-one (1.94 g, 6.1 mmol) was dissolved in EtOH and added dropwise to a NaOEt solution, prepared *in situ* by dissolving sodium (280 mg) in dry EtOH (70 mL) under N<sub>2</sub>. The mixture was stirred at room temperature for one hour, concentrated and acidified with 6N HCl to pH=5. This resulted in a yellow-orange solid, which was collected by filtration and dried to give the product as a medium brown solid; MS: 301 (M+H) and 255.

10

Step C. 2-(2,5-Dimethyl-3-furyl)-6-ethoxycarbonyl-4-(2-fluorophenylmethyl)pyrrolo[1,2-a]pyrimid-7-one


2-(2,5-Dimethyl-3-furyl)-4H-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one (1.83 g, 6.1 mmol) was suspended in DME (10 mL), followed by addition of TBAF (12.2 mL, 1M solution in THF, 12.2 mmol), and then 2-fluorobenzyl bromide. The solution was stirred at room temperature overnight. A solid precipitate was collected by filtration and washed with Et<sub>2</sub>O to yield the product; MS: 409 (M+H) and 363.

20

Step D. 2-(2,5-Dimethyl-3-furyl)-1-{N-methyl-N-[2-(2-pyridyl)ethyl]aminomethyl}-6-ethoxycarbonyl-4-(2-fluorophenylmethyl)pyrrolo[1,2-a]pyrimid-7-one

2-(2,5-Dimethyl-3-furyl)-6-ethoxycarbonyl-4-(2-fluorophenylmethyl)-pyrrolo[1,2-a]pyrimid-7-one (50mg, 122μmol) was added into a solution of formaldehyde (5 μL, 184 μmol) and a secondary amine (184 μmol) in acetic acid (2 mL). The resulting solution was stirred at room temperature for ten minutes, and then 50°C for another ten minutes. HOAc was evaporated and the residue was diluted with DCM and purified by prep-TLC (MeOH/DCM – 1:9) to yield the desired product, which was characterized by proton NMR and mass spectra.

Following the above procedures, the following compounds were prepared.



5


No.	$-\text{C}(\text{R}_3\text{R}_{3a})_m\text{NR}_1\text{R}_2$	MS (M+H)
76	$-\text{CH}_2\text{N}(\text{Me})(\text{CH}_2\text{CH}_2\text{-2-Py})$	557
77	$-\text{CH}_2\text{N}(\text{Me})(\text{Bz})$	442



EXAMPLES 78-84

1-{N-METHYL-N-[2-(2-PYRIDYL)ETHYL]AMINOMETHYL-3-FLUORO-4-(2-  
FLUOROBENZYL)-2-[4-(2-METHYLPROPYLOXY)PHENYL]-6-  
(ETHYLOXYCARBONYL)PYRROLO[1,2-A]PYRIMID-7-ONE


5




78

Step A      Fluoroacetamidine


10



HCl gas was bubbled into fluoroacetonitrile (11g, 186 mmol) at 0-20 °C until the reaction mixture solidified. Precooled EtOH (40 mL) was added to solid at –  
15 50 °C and the reaction was allowed to warm to room temperature overnight. Ether (200 mL) was added and the solid product *i* was filtered and washed with ether to give a total of 15.72 g of white solid (yield = 75%).

Step B Ethyl-(2-fluoromethylpyrimid-4-one)-5-carboxylate


5 Sodium hydroxide (4.0 g, 100 mmol) was added to a mixture of amidine *i* (5.63 g, 50 mmol) and ester *ii* (11.1 mL, 55 mmol) in EtOH (250 mL). The suspension was heated at reflux for 7 hr. After cooling to room temperature, the mixture was poured into water and acidified with a 10% HCl solution. Extraction with EtOAc followed by evaporation and trituration with ether gave pyrimidone *iii* as a solid  
10 (2.59 g, 26 % yield).

Step C 4'-(2-methylpropyloxy)acetophenone

15


4'-Hydroxyacetophenone *iv* (6.81 g, 50 mmol) was dissolved in EtOH (170 mL). Potassium carbonate (13.8 g, 100 mmol) and 1-bromo-2-methylpropane (6 mL, 55 mmol) were added and the reaction refluxed for 50 hr. Water (500 mL) was added followed by extraction with EtOAc. Evaporation of the organic layer after  
20 washes with 1M sodium hydroxide and brine gave *v* as an amber oil (3.95 g, 41% yield).

Step D      2-Bromo-4'-(2-methylpropyloxy)acetophenone




- 5                      Acetophenone *v* (3.5 g, 18.2 mmol) and CuBr<sub>2</sub> (8.14 g, 36.5 mmol) in chloroform/EtOAc (1;1, 35 mL) were heated at reflux for 2 hr. After filtration, the organic layer was washed, dried, filtered, and evaporated to give alpha-bromoketone *vi* (4.4 g, 89% yield).

10    Step E      Ethyl-2-fluoroethyl-3-[4-(2-methylpropyloxy)phenyl]carbonylmethyl-6-(ethyloxycarbonyl)pyrimid-4-one-5-carboxylate



- 15                      Tetrabutylammonium fluoride in THF (9.0 mL, 1.0M) was added to a suspension of *iii* (1.0 g, 5 mmol) in dimethoxyethane (30 mL). After 30 min, bromoketone *vi* (1.49 g, 5.5 mmol) in DME (2 mL) was added and the reaction mixture was stirred at room temperature overnight. Column chromatography using hexane/ethyl acetate as elutant gave isomer *vii* (794 mg, 41% yield) and product *viii* (434 mg, 22%).

Step F      3-Fluoro-2-[4-(2-methylpropyloxy)phenyl]-6-  
(ethyloxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one




5

Pyrimidone ester *viii* (430 mg, 1.1 mmol) was added to a solution of sodium ethoxide (63 mg Na in 14 mL EtOH) and the reaction mixture was stirred at room temperature for 4 hr. Acidification of the reaction mixture with 10% HCl resulted in a fine precipitate which was filtered and combined with an EtOAc wash resulting in solid *ix* (410mg, 99% yield).

10

Step G      3-Fluoro-4-(2-fluorobenzyl)-2-[4-(2-methylpropyloxy)phenyl]-6-  
(ethyloxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one




15

A solution of 1.0 M tetrabutylammonium fluoride in THF (1.21 mL) was added to a suspension of *ix* (410 mg, 1.1 mmol) in DME (8 mL). The resulting solution was stirred for 30 minutes. 2-Fluorobenzylbromide (0.16 mL, 1.3 mmol) was added and the reaction mixture was stirred for 19 hours. Workup involving extraction with EtOAc, aqueous wash of the EtOAc layer, and chromatography with EtOAc/hexane gave *x* (116 mg, 22%).

20


Step H 1-{N-Methyl-N-[2-(2-pyridyl)ethyl]aminomethyl-3-fluoro-4-(2-fluorobenzyl)-2-[4-(2-methylpropyloxy)phenyl]-6-(ethyloxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one

5



Pyrrolopyrimidone ester x (30 mg, 0.0625 mmol) was added to glacial acetic acid (1 mL), formaldehyde (2 drops), and 2-(2-methylaminoethyl)pyridine (2 drops). After 1 hour, extraction with EtOAc, purification by prep TLC using  $\text{CHCl}_3/\text{MeOH}/\text{NH}_4\text{OH}$ , and trituration with ether gave the titled product, 71, as a white solid (10 mg, 26%).

Following procedures similar to that described above, the compounds listed below were also prepared.




Ex.	R	R <sub>1</sub>	MS (M+H)
79	4-(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> O-	(2-Pyridyl)CH <sub>2</sub> CH <sub>2</sub> -	629
80	4-(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> O-	Bn	614
81	4-(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> O-	(2-Furyl)CH <sub>2</sub> -	604
82	3-CH <sub>3</sub> O-	Bn	572
83	3-CH <sub>3</sub> O-	(2-Furyl)CH <sub>2</sub> -	562
84	3-CH <sub>3</sub> O-	(2-Pyridyl)CH <sub>2</sub> CH <sub>2</sub> -	587

It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications  
5 may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## Claims

We claim:

1. A compound having the following structure:



and stereoisomers, prodrugs and pharmaceutically acceptable salts thereof,

wherein:

$m$  is an integer from 1 to 6;

$R_1$  is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, aryl( $CR_{3c}R_{3d}$ ) $_n$ , substituted aryl( $CR_{3c}R_{3d}$ ) $_n$ , heteroaryl( $CR_{3c}R_{3d}$ ) $_n$  or substituted heteroaryl( $CR_{3c}R_{3d}$ ) $_n$ ;

$R_2$  is hydrogen, alkyl or substituted alkyl;

or  $R_1$  and  $R_2$  taken together with the nitrogen atom to which they are attached form a heterocycle ring or a substituted heterocycle ring;

$R_{3a}$ ,  $R_{3b}$ ,  $R_{3c}$  and  $R_{3d}$  are the same or different and independently at each occurrence hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, thioalkyl, amino, alkylamino, dialkylamino, cyano, halogen,  $-C(=O)OR_7$  or  $-C(=O)NR_7R_8$ ;

or  $R_{3a}$  and  $R_{3b}$ , or  $R_{3c}$  and  $R_{3d}$ , taken together with the carbon atom to which they are attached form a carbocyclic ring or substituted carbocyclic ring;

or  $R_{3a}$  and  $R_1$ , taken together with the carbon atom and nitrogen atom, respectively, to which they are attached form a heterocyclic ring or substituted heterocyclic ring;

R<sub>4</sub> is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

R<sub>5</sub> is hydrogen, halogen, cyano, alkyl, substituted alkyl, hydroxy, alkoxy, thioalkyl or mono- or di-alkylamine;

R<sub>6</sub> is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, substituted heterocycle, -OR<sub>7</sub>, -SR<sub>7</sub>, -SOR<sub>7</sub>, -SO<sub>2</sub>R<sub>7</sub>, -OSO<sub>2</sub>R<sub>7</sub>, -SO<sub>2</sub>OR<sub>7</sub>, -SO<sub>2</sub>NR<sub>7</sub>R<sub>8</sub>, -NR<sub>9</sub>SO<sub>2</sub>R<sub>7</sub>, -C(=O)R<sub>7</sub>, -C(=O)OR<sub>7</sub>, -OC(=O)R<sub>7</sub>, -NR<sub>7</sub>R<sub>8</sub> -C(=O)NR<sub>7</sub>R<sub>8</sub>, -OC(=O)NR<sub>7</sub>R<sub>8</sub>, -NR<sub>9</sub>C(=O)R<sub>7</sub>, -NR<sub>9</sub>C(=O)NR<sub>7</sub>R<sub>8</sub>, -NR<sub>8</sub>C(=O)OR<sub>7</sub> or -C(OH)R<sub>7</sub>R<sub>8</sub>;

R<sub>7</sub>, R<sub>8</sub> and R<sub>9</sub> are the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

or R<sub>7</sub> and R<sub>8</sub> taken together with the nitrogen atom to which they are attached form a heterocycle ring or a substituted heterocycle ring;

*n* is an integer from 1 to 6; and

B and Ar are as follows:

B is nitrogen or CR<sub>10</sub> when Ar is heteroaryl or substituted heteroaryl and R<sub>10</sub> is hydrogen; or

B is CR<sub>10</sub> when Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl and R<sub>10</sub> is halogen, cyano, nitro, amino, mono- or di-alkylamino or alkyl.

2. The compound of claim 1 wherein

B is nitrogen or CR<sub>10</sub>;

R<sub>10</sub> is hydrogen; and

Ar is heteroaryl or substituted heteroaryl.

3. The compound of claim 1 wherein

B is CR<sub>10</sub>;


R<sub>10</sub> is halogen, cyano, nitro, amino, mono- or di-alkylamino or alkyl;

and

Ar is aryl, substituted aryl, heteroaryl or substituted heteroaryl.



4. The compound of claim 2 wherein B is nitrogen and Ar is heteroaryl.
5. The compound of claim 4 having the following structure:



wherein


$A_1, A_3$  and  $A_4$  are the same or different and independently nitrogen or CH;

$A_2$  is oxygen, sulfur, NH, N=N or N=CH; and


$R_a, R_b, R_c$  and  $R_d$  are optional substituents that are the same or different and independently halogen, nitro, cyano, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, hydroxy, alkoxy, aryloxy, thiol, thioalkyl, thioaryl, sulfonylalkyl, sulfonylaryl, amino, mono- or di-alkylamino, mono- or di-arylamino, -COOalkyl, -COOaryl, -CONHalkyl, -CONHaryl, -CON(alkyl)<sub>2</sub>, -CON(aryl)<sub>2</sub>, -NHCOalkyl, -NHCOaryl, -N(alkyl)COalkyl, -N(alkyl)COaryl, -NHSO<sub>2</sub>alkyl, -NHSO<sub>2</sub>aryl, N(alkyl)SO<sub>2</sub>alkyl, -N(alkyl)SO<sub>2</sub>aryl, -NHCONHalkyl or -NHCONHaryl;

or  $R_a$  and  $R_b$  taken together with the atoms to which they are attached form aryl, substituted aryl, heteroaryl or substituted heteroaryl.

6. The compound of claim 2 wherein B is CR<sub>10</sub>, Ar is heteroaryl, and R<sub>10</sub> is hydrogen.
7. The compound of claim 6 having the following structure:




8. The compound of claim 3 wherein B is CR<sub>10</sub> and Ar is heteroaryl.
9. The compound of claim 8 having the following structure:




10. The compound of claim 1 wherein R<sub>1</sub> is arylalkyl, substituted arylalkyl or heteroarylalkyl.
11. The compound of claim 10 wherein aralkyl is benzyl and substituted arylalkyl is substituted benzyl.
12. The compound of claim 10 wherein heteroarylalkyl is -CH<sub>2</sub>(heteroaryl) or -CH<sub>2</sub>CH<sub>2</sub>(heteroaryl).
13. The compound of claim 1 wherein R<sub>2</sub> is alkyl.
14. The compound of claim 13 wherein alkyl is methyl.

15. The compound of claim 1 wherein  $R_1$  and  $R_2$  taken together with the nitrogen atom to which they are attached form a heterocycle or substituted heterocycle.
16. The compound of claim 1 wherein  $R_{3a}$  is hydrogen.
17. The compound of claim 1 wherein  $R_{3b}$  is hydrogen.
18. The compound of claim 16 wherein  $R_{3b}$  is hydrogen.
19. The compound of claim 1 where  $m$  is 1.
20. The compound of claim 1 wherein  $R_4$  is arylalkyl or substituted arylalkyl.
21. The compound of claim 14 wherein arylalkyl or substituted arylalkyl is benzyl or substituted benzyl.
22. The compound of claim 1 wherein  $R_5$  is hydrogen.
23. The compound of claim 1 wherein  $R_6$  is  $-C(=O)OR_7$ .
24. The compound of claim 23 wherein  $R_7$  is alkyl.
25. The compound of claim 1 wherein  $R_6$  is  $-C(=O)NR_7R_8$ .
26. The compound of claim 13 wherein  $R_7$  and  $R_8$  are the same or different and independently alkyl or substituted alkyl.
27. The compound of claim 25 wherein  $R_7$  and  $R_8$  taken together with the nitrogen atom to which they are attached form a heterocycle or substituted heterocycle.

28. The compound of any one of claims 5, 7 or 9 wherein the heteroaryl moiety



has one of the following structures:



29. The compound of claim 1 wherein  $R_{10}$  is halogen or cyano.

30. The compound of claim 1 wherein the compound is:

2-(2,5-Dimethylfuran-3-yl)-3-[N-methyl-(2-pyridylethyl)]aminomethyl-5-(3-pentoxycarbonyl)-7-(2-fluorobenzyl)imidazolo[1,2-a]pyrimid-4-one;

2-(1-Methylpyrrol-3-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;

2-(Thiophen-2-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;

2-(2,5-Dimethylfuran-3-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;

2-(Pyrid-3-yl)-3-{N-[2-(2-pyridyl)ethyl]-N-methylaminomethyl}-5-(3-methoxyphenyl)-6-methyl-7-(2-fluorophenylmethyl)imidazolo[1,2-a]pyrimid-4-one;

1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(2,5-dimethylfuran-3-yl)-4-(2-fluorobenzyl)-6-(3-pentoxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one;

1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-cyanobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2-methoxybenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

1-(N-Benzyl-N-methyl)aminomethyl-2-(4-methoxyphenyl)-3-cyano-4-(2,4-difluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

1-(N-Benzyl-N-methyl)aminomethyl-2-(4-isobutoxyphenyl)-3-cyano-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one;

1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(2,5-dimethylfuran-3-yl)-4-(2-fluorobenzyl)-6-(3-pentoxycarbonyl)pyrrolo[1,2-a]pyrimid-7-one;

1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(2,5-dimethylfuran-3-yl)-4-(2-fluorobenzyl)-6-(3-pentoxycarbonyl)imidazolo[1,2-a]pyrimid-7-one;

1-(N-Benzyl-N-methyl)aminomethyl-2-(4-isobutoxyphenyl)-3-fluoro-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one; or

1-[N-Methyl-(2-pyridylethyl)]aminomethyl-2-(4-isobutoxyphenyl)-3-fluoro-4-(2-fluorobenzyl)-6-ethoxycarbonylpyrrolo[1,2-a]pyrimid-7-one.

31. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

32. A method for antagonizing gonadotropin-releasing hormone in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1.

33. A method for treating a sex-hormone related condition of a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 31.

34. The method of claim 33 wherein the sex-hormone related condition is cancer, benign prostatic hypertrophy or myoma of the uterus.

35. The method of claim 34 wherein the cancer is prostatic cancer, uterine cancer, breast cancer or pituitary gonadotroph adenomas.

36. The method of claim 33 wherein the sex-hormone related condition is endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty.

37. A method for preventing pregnancy of a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 31.

38. A method for treating lupus erythematosus, irritable bowel syndrome, premenstrual syndrome, hirsutism, short stature or sleep disorders in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 31.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/13108

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/505 A61P15/00 //(C07D487/04,209:00,  
239:00),(C07D487/04,235:00,239:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 33831 A (TAKEDA CHEMICAL INDUSTRIES, LTD.) 8 July 1999 (1999-07-08) cited in the application claims 1-39	1-38
Y	US 5 744 479 A (S. FURUYA ET AL.) 28 April 1998 (1998-04-28) cited in the application claims 1-28	1-38
P,Y	WO 99 51232 A (MERCK & CO., INC.) 14 October 1999 (1999-10-14) claims 1-29	1-38



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

22 August 2000

Date of mailing of the international search report

14/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

# INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

PCT/US 00/13108

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9933831	A	08-07-1999	AU 1687199 A	19-07-1999
			JP 11315079 A	16-11-1999
US 5744479	A	28-04-1998	AU 7333396 A	07-05-1997
			CN 1200124 A	25-11-1998
			EP 0862573 A	09-09-1998
			WO 9714697 A	24-04-1997
			JP 9169767 A	30-06-1997
WO 9951232	A	14-10-1999	AU 3118399 A	25-10-1999